Rosuvastatin at doses of 5 to 80 mg significantly reduced mean triglyceride levels by 18% to 40% compared with a 2.9% increase with placebo (P≤0.001).
RCT (n=156)
Double-blind
parallel-group
Yes
Does rosuvastatin improve triglyceride levels and lipid profiles in patients with hypertriglyceridemia?
Rosuvastatin significantly reduces triglyceride levels and improves atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia.
p-value: p=≤ 0.001
BACKGROUND: We examined the effects of rosuvastatin treatment on triglyceride levels and lipid measures in a parallel-group multicenter trial (4522IL/0035) in patients with hypertriglyceridemia (Fredrickson Type IIb or IV). METHODS: After a 6-week dietary lead-in period while on a National Cholesterol Education Program step I diet, 156 patients with fasting triglyceride levels >/= 300 and 5 mg. The occurrence of adverse events was generally low and not dose related, although some adverse events occurred more frequently in the rosuvastatin 80 mg group. CONCLUSIONS: Rosuvastatin reduced triglyceride levels and improved the overall atherogenic and atheroprotective lipid profiles in hypertriglyceridemic patients.
Hunninghake 외 (목요일)은 고트리글리세리드혈증(n=156)에서 무작위 대조시험을 실시하였다. 로수바스타틴 대 위약은 주 6회의 총 혈청 트리글리세리드 수치의 기저선 대비 평균 백분율 변화를 평가하였다(p=≤ 0.001). 5 mg에서 80 mg의 로수바스타틴은 위약의 2.9% 증가와 비교하여 평균 트리글리세리드 수치를 18%에서 40%까지 유의미하게 줄였다(P≤0.001).